Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Cabozantinib
kidney cancer treatment
metastatic renal cell carcinoma
post-progression survival
treatment beyond progression
Journal
Expert review of anticancer therapy
ISSN: 1744-8328
Titre abrégé: Expert Rev Anticancer Ther
Pays: England
ID NLM: 101123358
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
6
11
2021
medline:
27
4
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Cabozantinib improves survival in metastatic renal cell carcinoma (mRCC) after prior antiangiogenics. The best treatment at disease progression (PD) is unknown. Being also a AXL/MET inhibitor, involved in acquired resistance, we hypothesized a prolonged tumor growth control in patients continuing cabozantinib despite PD. This retrospective multicenter study enrolled patients receiving cabozantinib after the first line between 2014 and 2020. We compared patients maintaining cabozantinib after first PD due to clinical benefit and good tolerability with those who changed therapy. The postprogression survival (PPS) of both was our primary endpoint. We analyzed 89 patients: 45 received cabozantinib beyond PD and 44 switched therapy. 40.4%, 31.5%, and 28.1% of patients received 1, 2, or >2 prior treatment, respectively. 84.3% were intermediate-poor International Metastatic Renal Cell Carcinoma Database risk. Patients continuing cabozantinib showed a higher response rate to cabozantinib before PD (46.7% vs 25%, p = 0.03) and were more heavily pretreated. Continuing cabozantinib showed a significantly longer PPS compared with switching therapy (median PPS 16.9 vs 13.2 months, HR 0.66, 95%CI 0.48-0.92, p = 0.011). We observed longer PPS in patients continuing cabozantinib beyond PD, suggesting that this could be an effective option.
Sections du résumé
BACKGROUND
BACKGROUND
Cabozantinib improves survival in metastatic renal cell carcinoma (mRCC) after prior antiangiogenics. The best treatment at disease progression (PD) is unknown. Being also a AXL/MET inhibitor, involved in acquired resistance, we hypothesized a prolonged tumor growth control in patients continuing cabozantinib despite PD.
RESEARCH DESIGN AND METHODS
METHODS
This retrospective multicenter study enrolled patients receiving cabozantinib after the first line between 2014 and 2020. We compared patients maintaining cabozantinib after first PD due to clinical benefit and good tolerability with those who changed therapy. The postprogression survival (PPS) of both was our primary endpoint.
RESULTS
RESULTS
We analyzed 89 patients: 45 received cabozantinib beyond PD and 44 switched therapy. 40.4%, 31.5%, and 28.1% of patients received 1, 2, or >2 prior treatment, respectively. 84.3% were intermediate-poor International Metastatic Renal Cell Carcinoma Database risk. Patients continuing cabozantinib showed a higher response rate to cabozantinib before PD (46.7% vs 25%, p = 0.03) and were more heavily pretreated. Continuing cabozantinib showed a significantly longer PPS compared with switching therapy (median PPS 16.9 vs 13.2 months, HR 0.66, 95%CI 0.48-0.92, p = 0.011).
CONCLUSIONS
CONCLUSIONS
We observed longer PPS in patients continuing cabozantinib beyond PD, suggesting that this could be an effective option.
Identifiants
pubmed: 34738499
doi: 10.1080/14737140.2022.2002688
doi:
Substances chimiques
Anilides
0
Pyridines
0
cabozantinib
1C39JW444G
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM